Ascentage Pharma Group (AAPG) is entering 2026 with growing commercial momentum in China and a pipeline nearing major global readouts, including two "potential blockbuster" drugs, Oppenheimer said Friday in a report.

Olverembatinib, used for certain hard-to-treat leukemias, remained the company's top seller in 2025, with revenue rising 81% to $62.2 million from a year earlier, the report said. Lisaftoclax, a pill for blood cancers such as chronic lymphocytic leukemia, added $10.1 million in its first five months on the market, giving Ascentage a second meaningful product line, Oppenheimer said.

This year will be dominated by enrollment across nine global registration-focused studies, setting up multiple programs for possible regulatory filings in 2027, the report said.

Oppenheimer also pointed to early signs of strategic alignment around pairing lisaftoclax with APG-3288, another cancer drug Ascentage is developing, in chronic lymphocytic leukemia, a combination that may offer patients an all-oral, time-limited treatment option.

Oppenheimer maintained its outperform rating on Ascentage stock with a $45 price target.

Price: 23.12, Change: +1.82, Percent Change: +8.56